Skip to main content

Table 4 Stratified MTCT rates in singleton pregnanciesa

From: Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland

  2003–2007 2008–2012
  n/N % (95 % CI) n/N % (95 % CI)
Overall MTCT rate 18/1633 1.1 (0.6–1.6) 12/2406 0.5 (0.2–0.8)
ᅟBy timing of LPV/r initiation
ᅟᅟBefore conception 2/333 0.6 (0.2–2.2) 2/635 0.3 (0.1–1.1)
ᅟᅟFirst trimester 0/33 0/77
ᅟᅟSecond trimester 8/858 0.9 (0.5–1.8) 5/1397 0.4 (0.2–0.8)
ᅟᅟThird trimester 8/376 2.1 (1.1–4.1) 5/264 1.9 (0.8–4.4)
ᅟBy baseline CD4+ T-cell count
ᅟᅟ<200 cells/mm3 3/157 1.9 (0.7–5.5) 2/206 1.0 (0.3–3.5)
ᅟᅟ200–349 cells/mm3 4/340 1.2 (0.5–3.0) 1/506 0.2 (0.04–1.1)
ᅟᅟ≥350 cells/mm3 4/600 0.7 (0.3–1.7) 2/1171 0.2 (0.1–0.6)
ᅟᅟMissing CD4+ T-cell count 7/536 1.3 (0.6–2.7) 7/523 1.3 (0.6–2.7)
  1. Abbreviations: MTCT mother-to-child transmission, CI confidence interval, LPV/r lopinavir/ritonavir
  2. aReported for the 4609 pregnancies where infant HIV status was available